DOI QR코드

DOI QR Code

Radiation-induced brain injury: retrospective analysis of twelve pathologically proven cases

  • Lee, Dong-Soo (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Yu, Mi-Na (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Jang, Hong-Seok (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Kim, Yeon-Sil (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Choi, Byung-Ock (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Kang, Young-Nam (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Lee, Youn-Soo (Department of Pathology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Kim, Dong-Chul (Department of Pathology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Hong, Yong-Kil (Department of Neurosurgery, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Jeun, Sin-Soo (Department of Neurosurgery, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Yoon, Sei-Chul (Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea)
  • Received : 2011.03.24
  • Accepted : 2011.06.15
  • Published : 2011.09.30

Abstract

Purpose: This study was designed to determine the influencing factors and clinical course of pathologically proven cases of radiation-induced brain injury (RIBI). Materials and Methods: The pathologic records of twelve patients were reviewed; these patients underwent surgery following radiotherapy due to disease progression found by follow-up imaging. However, they were finally diagnosed with RIBI. All patients had been treated with 3-dimensional conventional fractionated radiotherapy and/or radiosurgery for primary or metastatic brain tumors with or without chemotherapy. The histological distribution was as follows: two falx meningioma, six glioblastoma multiform (GBM), two anaplastic oligodendroglioma, one low grade oligodendroglioma, and one small cell lung cancer with brain metastasis. Results: Radiation necrosis was noted in eight patients and the remaining four were diagnosed with radiation change. Gender (p = 0.061) and biologically equivalent dose $(BED)_3$ (p = 0.084) were the only marginally influencing factors of radiation necrosis. Median time to RIBI was 7.3 months (range, 0.5 to 61 months). Three prolonged survivors with GBM were observed. In the subgroup analysis of high grade gliomas, RIBI that developed <6 months after radiotherapy was associated with inferior overall survival rates compared to cases of RIBI that occurred ${\geq}6$ months (p = 0.085). Conclusion: Our study demonstrated that RIBI could occur in early periods after conventional fractionated brain radiotherapy within normal tolerable dose ranges. Studies with a larger number of patients are required to identify the strong influencing factors for RIBI development.

Keywords

References

  1. Tsien C, Moughan J, Michalski JM, et al. Phase I threedimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 2009;73:699-708. https://doi.org/10.1016/j.ijrobp.2008.05.034
  2. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-72. https://doi.org/10.1016/S0140-6736(04)16250-8
  3. Floyd NS, Woo SY, I BS, et al. Hypofractionated intensitymodulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004;58:721-6. https://doi.org/10.1016/S0360-3016(03)01623-7
  4. Roberge D, Petrecca K, El Refae M, Souhami L. Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases. J Neurooncol 2009;95:95-9. https://doi.org/10.1007/s11060-009-9899-z
  5. Bese NS, Uzel O, Turkan S, Okkan S. Continuous hyperfractionated accelerated radiotherapy in the treatment of highgrade astrocytomas. Radiother Oncol 1998;47:197-200. https://doi.org/10.1016/S0167-8140(97)00233-8
  6. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
  7. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S20-7.
  8. Langley RE, Bump EA, Quartuccio SG, Medeiros D, Braunhut SJ. Radiation-induced apoptosis in microvascular endothelial cells. Br J Cancer 1997;75:666-72. https://doi.org/10.1038/bjc.1997.119
  9. Lyubimova N, Hopewell JW. Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation-induced CNS injury. Br J Radiol 2004;77:488-92. https://doi.org/10.1259/bjr/15169876
  10. Nguyen V, Gaber MW, Sontag MR, Kiani MF. Late effects of ionizing radiation on the microvascular networks in normal tissue. Radiat Res 2000;154:531-6. https://doi.org/10.1667/0033-7587(2000)154[0531:LEOIRO]2.0.CO;2
  11. Li YQ, Jay V, Wong CS. Oligodendrocytes in the adult rat spinal cord undergo radiation-induced apoptosis. Cancer Res 1996;56:5417-22.
  12. Chow BM, Li YQ, Wong CS. Radiation-induced apoptosis in the adult central nervous system is p53-dependent. Cell Death Differ 2000;7:712-20. https://doi.org/10.1038/sj.cdd.4400704
  13. Lowenberg-Scharenberg K, Bassett RC. Amyloid degeneration of the human brain following X-ray therapy. J Neuropathol Exp Neurol 1950;9:93-102. https://doi.org/10.1097/00005072-195001000-00006
  14. Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006;65:499-508. https://doi.org/10.1016/j.ijrobp.2005.12.002
  15. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-61. https://doi.org/10.1016/S1470-2045(08)70125-6
  16. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 2009;50:1962-8. https://doi.org/10.2967/jnumed.109.065904
  17. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol 2010;97:73-80. https://doi.org/10.1007/s11060-009-9991-4
  18. Price SJ. The role of advanced MR imaging in understanding brain tumour pathology. Br J Neurosurg 2007;21:562-75. https://doi.org/10.1080/02688690701700935
  19. Lee AW, Kwong DL, Leung SF, et al. Factors affecting risk of symptomatic temporal lobe necrosis: signifi cance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 2002;53:75-85. https://doi.org/10.1016/S0360-3016(02)02711-6
  20. Chin LS, Ma L, DiBiase S. Radiation necrosis following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow up. J Neurosurg 2001;94:899-904. https://doi.org/10.3171/jns.2001.94.6.0899
  21. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000;47:291-8. https://doi.org/10.1016/S0360-3016(99)00507-6
  22. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-7. https://doi.org/10.1200/JCO.2007.14.8163
  23. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22:633-8. https://doi.org/10.1097/WCO.0b013e328332363e
  24. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82:81-3. https://doi.org/10.1007/s11060-006-9241-y
  25. Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006;8:253-60. https://doi.org/10.1215/15228517-2006-005
  26. Yang SH, Hong YK, Yoon SC, et al. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma. Oncol Rep 2007;17:1359-64.
  27. Budrukkar A, Jalali R, Dutta D, et al. Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol 2009;95:413-9. https://doi.org/10.1007/s11060-009-9939-8

Cited by

  1. Mass spectrometry imaging as a tool for surgical decision‐making vol.48, pp.11, 2011, https://doi.org/10.1002/jms.3295
  2. Predictive Risk of Radiation Induced Cerebral Necrosis in Pediatric Brain Cancer Patients after VMAT Versus Proton Therapy vol.7, pp.2, 2011, https://doi.org/10.3390/cancers7020617
  3. Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer vol.33, pp.3, 2015, https://doi.org/10.3857/roj.2015.33.3.207
  4. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation vol.2, pp.1, 2011, https://doi.org/10.1093/noajnl/vdaa057
  5. Feasibility of a mini-pig model of radiation-induced brain injury to one cerebral hemisphere vol.16, pp.1, 2011, https://doi.org/10.1186/s13014-021-01753-1